Sodium phenylbutyrate controls neuroinflammatory and antioxidant activities and protects dopaminergic neurons in mouse models of Parkinson's disease

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Roy, Avik ^a   Ghosh, Anamitra ^a   Jana, Arundhati ^a   Liu, Xiaojuan ^b   Brahmachari, Saurav ^a   Gendelman, Howard E ^c   Pahan, Kalipada ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; CHOLESTEROL; DOPAMINE; GERANYLGERANYL TRANSFERASE INHIBITOR; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; MUTANT PROTEIN; P21 ACTIVATED KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21; TRANSFERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN NERVE CELL; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOPAMINERGIC NERVE CELL; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; FETUS; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MICROGLIA; MOUSE; NEUROMODULATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; SUBSTANTIA NIGRA; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; CYTOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINERGIC NEURONS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; MALE; MEVALONIC ACID; MICE; MICE, INBRED C57BL; MICROGLIA; MOTOR ACTIVITY; NEUROGLIA; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; ONCOGENE PROTEIN P21(RAS); PARKINSON DISEASE; PHENYLBUTYRATES; REACTIVE OXYGEN SPECIES;

EID: 84862487151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038113     Document Type: Article

References (50)

1. Dauer W, Przedborski S, (2003) Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
2. Gao HM, Liu B, Zhang W, Hong JS, (2003) Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol Sci 24: 395-401.
3. Bokoch GM, Knaus UG, (2003) NADPH oxidases: not just for leukocytes anymore! Trends Biochem Sci 28: 502-508.
4. Wu DC, Teismann P, Tieu K, Vila M, Jackson-Lewis V, et al. (2003) NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A 100: 6145-6150.
5. Zhang W, Wang T, Qin L, Gao HM, Wilson B, et al. (2004) Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase. Faseb J 18: 589-591.
6. Nagatsu T, Mogi M, Ichinose H, Togari A, (2000) Changes in cytokines and neurotrophins in Parkinson's disease. J Neural Transm.
7. Giulian D, Baker TJ, (1986) Characterization of ameboid microglia isolated from developing mammalian brain. J Neurosci 6: 2163-2178.
8. Roy A, Fung YK, Liu X, Pahan K, (2006) Up-regulation of microglial CD11b expression by nitric oxide. J Biol Chem 281: 14971-14980.
9. Jana M, Jana A, Liu X, Ghosh S, Pahan K, (2007) Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia. J Immunol 179: 4142-4152.
10. Saha RN, Jana M, Pahan K, (2007) MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65. J Immunol 179: 7101-7109.
11. Jana M, Jana A, Pal U, Pahan K, (2007) A simplified method for isolating highly purified neurons, oligodendrocytes, astrocytes, and microglia from the same human fetal brain tissue. Neurochem Res 32: 2015-2022.
12. Liu X, Jana M, Dasgupta S, Koka S, He J, et al. (2002) Human immunodeficiency virus type 1 (HIV-1) tat induces nitric-oxide synthase in human astroglia. J Biol Chem 277: 39312-39319.
13. Khasnavis S, Pahan K, (2012) Sodium Benzoate, a Metabolite of Cinnamon and a Food Additive, Upregulates Neuroprotective Parkinson Disease Protein DJ-1 in Astrocytes and Neurons. J Neuroimmune Pharmacol 7: 424-435.
14. Saha RN, Liu X, Pahan K, (2006) Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 1: 212-222.
15. Brahmachari S, Jana A, Pahan K, (2009) Sodium benzoate, a metabolite of cinnamon and a food additive, reduces microglial and astroglial inflammatory responses. J Immunol 183: 5917-5927.
16. Roy A, Jana A, Yatish K, Freidt MB, Fung YK, et al. (2008) Reactive oxygen species up-regulate CD11b in microglia via nitric oxide: Implications for neurodegenerative diseases. Free Radic Biol Med 45: 686-699.
17. Ghosh A, Roy A, Matras J, Brahmachari S, Gendelman HE, et al. (2009) Simvastatin inhibits the activation of p21ras and prevents the loss of dopaminergic neurons in a mouse model of Parkinson's disease. J Neurosci 29: 13543-13556.
18. Meredith GE, Totterdell S, Potashkin JA, Surmeier DJ, (2008) Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord 14: S112-115.
19. Roy A, Pahan K, (2011) Prospects of statins in Parkinson disease. Neuroscientist 17: 244-255.
20. Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, et al. (2003) D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest 112: 892-901.
21. Pahan K, Liu X, McKinney MJ, Wood C, Sheikh FG, et al. (2000) Expression of a dominant-negative mutant of p21(ras) inhibits induction of nitric oxide synthase and activation of nuclear factor-kappaB in primary astrocytes. J Neurochem 74: 2288-2295.
22. Benner EJ, Mosley RL, Destache CJ, Lewis TB, Jackson-Lewis V, et al. (2004) Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 101: 9435-9440.
23. Jana M, Anderson JA, Saha RN, Liu X, Pahan K, (2005) Regulation of inducible nitric oxide synthase in proinflammatory cytokine-stimulated human primary astrocytes. Free Radic Biol Med 38: 655-664.
24. Jana M, Liu X, Koka S, Ghosh S, Petro TM, et al. (2001) Ligation of CD40 stimulates the induction of nitric-oxide synthase in microglial cells. J Biol Chem 276: 44527-44533.
25. Pahan K, Sheikh FG, Namboodiri AM, Singh I, (1997) Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100: 2671-2679.
26. Xie QW, Kashiwabara Y, Nathan C, (1994) Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 269: 4705-4708.
27. Olanow CW, Tatton WG, (1999) Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 22: 123-144.
28. Qureshi GA, Baig S, Bednar I, Sodersten P, Forsberg G, et al. (1995) Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6: 1642-1644.
29. Ghosh A, Roy A, Liu X, Kordower JH, Mufson EJ, et al. (2007) Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A 104: 18754-18759.
30. Lahaie-Collins V, Bournival J, Plouffe M, Carange J, Martinoli MG, (2008) Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP+-induced oxidative stress. Oxid Med Cell Longev 1: 54-62.
31. Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, et al. (2010) Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease. Glia 58: 588-598.
32. Wang Y, Zhang X, Li C, Zhao J, Wei E, et al. (2012) Involvement of 5-lipoxygenase/cysteinyl leukotriene receptor 1 in rotenone- and MPP+-induced BV2 microglial activation. Mol Neurodegener 7: S24.
33. Jana A, Pahan K, (2004) Fibrillar amyloid-beta peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase. Implications for Alzheimer's disease. J Biol Chem 279: 51451-51459.
34. Jana A, Pahan K, (2004) Human immunodeficiency virus type 1 gp120 induces apoptosis in human primary neurons through redox-regulated activation of neutral sphingomyelinase. J Neurosci 24: 9531-9540.
35. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB, (2000) Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 74: 2213-2216.
36. Hunot S, Boissiere F, Faucheux B, Brugg B, Mouatt-Prigent A, et al. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 72: 355-363.
37. Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, et al. (2002) Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci 22: 1763-1771.
38. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, et al. (2011) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31: 1081-1092.
39. Brahmachari S, Fung YK, Pahan K, (2006) Induction of glial fibrillary acidic protein expression in astrocytes by nitric oxide. J Neurosci 26: 4930-4939.
40. Butler R, Bates GP, (2006) Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 7: 784-796.
41. Ozcan U, Yilmaz E, Ozcan L, Furuhashi M, Vaillancourt E, et al. (2006) Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes. Science 313: 1137-1140.
42. Maestri NE, Brusilow SW, Clissold DB, Bassett SS, (1996) Long-term treatment of girls with ornithine transcarbamylase deficiency. N Engl J Med 335: 855-859.
43. Bolden JE, Peart MJ, Johnstone RW, (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769-784.
44. Phuphanich S, Baker SD, Grossman SA, Carson KA, Gilbert MR, et al. (2005) Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study. Neuro Oncol 7: 177-182.
45. Saha RN, Pahan K, (2006) Signals for the induction of nitric oxide synthase in astrocytes. Neurochem Int 49: 154-163.
46. Hancock JF, Cadwallader K, Marshall CJ, (1991) Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). Embo J 10: 641-646.
47. Kikuchi A, Williams LT, (1994) The post-translational modification of ras p21 is important for Raf-1 activation. J Biol Chem 269: 20054-20059.
48. Liu Y, Denlinger CE, Rundall BK, Smith PW, Jones DR, (2006) Suberoylanilide hydroxamic acid induces Akt-mediated phosphorylation of p300, which promotes acetylation and transcriptional activation of RelA/p65. J Biol Chem 281: 31359-31368.
49. Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, et al. (2011) Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem 286: 14941-14951.
50. Thibault A, Cooper MR, Figg WD, Venzon DJ, Sartor AO, et al. (1994) A phase I and pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res 54: 1690-1694.